Teva Pharmaceutical Non-GAAP EPS of $0.66 beats by $0.04, revenue of $4.18B misses by $90M

Teva Pharmaceutical press release (NYSE:TEVA): Q2 Non-GAAP EPS of $0.66 beats by $0.04.
Revenue of $4.18B (+0.5% Y/Y) misses by $90M.
Increase of 2025 key innovative products revenues and EPS outlook and reaffirms all other outlook components:
- Revenues of $16.8 ‐ $17.2 billion (reaffirmed) vs consensus of $16.96B
- Non‐GAAP operating income of $4.3 ‐ $4.6 billion (reaffirmed)
- Adjusted EBITDA of $4.7 ‐ $5.0 billion (reaffirmed)
- Non‐GAAP diluted EPS of $2.50 ‐ $2.65 (+$0.05 at the low-end) vs consensus of $2.54
- Free cash flow of $1.6 ‐ $1.9 billion (reaffirmed)

More on Teva Pharmaceutical